Die Inhalte stammen aus dem NEJM Journal Watch Oncology & Hematology, der von der NEJM Group, a Division of the Massachusetts Medical Society, hergestellt und veröffentlich wird. Alle Rechte sind vorbehalten und alle Inhalte sind urheberrechtlich geschützt. Universimed und unsere Sponsoren ermöglichen Ihnen den Zugang zu diesen Inhalten als professionelle Unterstützung.
Trastuzumab Fails as Adjuvant Therapy in Esophageal Cancer
There were no significant differences in survival or surgical outcomes between patients treated with or without trastuzumab.
Preserving Ovarian Function in Women with Breast Cancer
Treatment with a gonadotropin-releasing hormone analog reduced the risk of premature ovarian insufficiency.
Safety of Antiplatelet Therapy in Patients with CNS Metastases
Antiplatelet therapy did not increase the rate of intracranial hemorrhage in patients with brain metastases.
Radioiodine After Thyroidectomy in Patients with Low-Risk Differentiated Thyroid Cancer?
In a randomized trial, radioiodine did not improve outcomes in such patients.
Intensification of ADT in Hormone-Sensitive Metastatic Prostate Cancer: An Evolving Paradigm
The addition of darolutamide to androgen deprivation therapy plus docetaxel increased survival.
Nivolumab Combination Therapy in Advanced Esophageal Squamous Cell Carcinoma
Nivolumab conferred a survival benefit when added to first-line chemotherapy or in combination with ipilimumab.
Cervical Cancer: Immunotherapy for All?
Women with recurrent cervical cancer after standard-of-care chemotherapy and bevacizumab lived longer when treated with the anti–PD-1 antibody cemiplimab.
Surgery vs. Radiation Therapy for High-Risk Localized Prostate Cancer
In an observational study, 5-year mortality was lower with radical prostatectomy.
Hydroxyurea vs. Pegylated Interferon in Essential Thrombocythemia and Polycythemia Vera
Response rates were similar with HU and peg-IFN in high-risk patients with ET and PV.